In 1981, Woodcock and colleagues1 published the first clinical study of opioids for the management of breathlessness in severe chronic obstructive pulmonary disease (COPD). They found that dihydrocodeine offered a short-term benefit but cautioned readers that “the risks of respiratory depression and addiction” necessitate careful monitoring and patient selection and that more studies were needed prior to “haphazard prescribing.”1(p1616)
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Widera EW. The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness. JAMA Intern Med. 2020;180(10):1315–1316. doi:10.1001/jamainternmed.2020.3133
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: